Pembrolizumab combinations therapy for mCRPC

Pembrolizumab combinations therapy for mCRPC

For metastatic castration-resistant prostate cancer (mCRPC) patients, three combination therapies having pembrolizumab offered anti-tumour activity.

In a study, the safety and effectiveness of pembrolizumab combination therapy were found in three groups of patients divided as per the pretreatment. In this study, patients in all the three groups were given pembrolizumab 200 mg intravenously every three weeks.

There were 84 patients in group A who were pretreated with docetaxel. They were given olaparib 300 mg tablet or 400 mg capsule two times a day. Group B patients were pretreated with either enzalutamide or abiraterone acetate.

They were given docetaxel at 75 mg/m2 intravenously every three weeks with oral prednisone at 5 mg two times a day along with pembrolizumab was given. This group has 104 patients.

Group C patients were pretreated with abiraterone acetate. They included 102 patients. They were given oral enzalutamide at 160 mg per day along with pembrolizumab.

The primary results were prostate specific antigen (PSA) response rate, objective response rate (ORR) and safety. PSA response was seen in 9% of patients in group A, 28% of patients in group B and 22% of patients in group C.

Measurable disease was seen in 48 (group A), 52 (group B) and 40 (group C) patients among the total of every group.

In patients having measurable disease and more than twenty-seven weeks of follow-up, the ORR was 8% in group A, 18% in group B and 12% in group C. The best reaction were two partial response, seven partial response and two complete response plus one partial response in group A, B, and C, correspondingly.

Median radiographic progression-free survival (rPFS) was 4.3 months, 8.3 months and 6.1 months in group A, B and C respectively. Median overall survival in the individual groups was 14.4 months, 20.4 months, and 20.4 months.
Deaths due to treatment-related adverse events were two in group A, two in group B and one in group C.

It was concluded that all three pembrolizumab combinations for mCRPC had shown anti-tumour activity. They also demonstrated that the tolerability profile, which was reliable with the individual profiles of each agent.

Source: ESMO
Link to the source:

[Last accessed on: 24 November, 2020]

Original title of article: Pembrolizumab combinations show promise in mCRPC
Translated by:

Disease area: Metastatic castration-resistant prostate cancer

Tags: Exploratory, Metastatic castration-resistant prostate cancer, Prostate, Chronic, Antineoplastic agents, Efficacy, Safety

Copyright © 2021 | Powered by: Admac Oncology